Adaptive Biotechnologies Corporation $ADPT Shares Acquired by Legato Capital Management LLC

Legato Capital Management LLC lifted its holdings in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 30.8% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 238,013 shares of the company’s stock after purchasing an additional 55,985 shares during the period. Legato Capital Management LLC owned approximately 0.16% of Adaptive Biotechnologies worth $3,561,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in ADPT. Xponance Inc. grew its stake in shares of Adaptive Biotechnologies by 29.3% in the third quarter. Xponance Inc. now owns 15,096 shares of the company’s stock worth $226,000 after acquiring an additional 3,419 shares in the last quarter. US Bancorp DE boosted its holdings in Adaptive Biotechnologies by 7.4% in the third quarter. US Bancorp DE now owns 127,153 shares of the company’s stock valued at $1,902,000 after purchasing an additional 8,738 shares during the period. Fox Run Management L.L.C. boosted its holdings in Adaptive Biotechnologies by 98.0% in the third quarter. Fox Run Management L.L.C. now owns 39,983 shares of the company’s stock valued at $598,000 after purchasing an additional 19,788 shares during the period. Counterpoint Mutual Funds LLC acquired a new position in Adaptive Biotechnologies during the 3rd quarter worth $557,000. Finally, AXQ Capital LP purchased a new stake in Adaptive Biotechnologies during the 3rd quarter worth about $277,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, insider Harlan S. Robins sold 8,120 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $19.00, for a total value of $154,280.00. Following the completion of the sale, the insider owned 1,179,524 shares in the company, valued at approximately $22,410,956. The trade was a 0.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Kyle Piskel sold 2,145 shares of the stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $18.46, for a total value of $39,596.70. Following the completion of the sale, the chief financial officer directly owned 216,637 shares of the company’s stock, valued at $3,999,119.02. The trade was a 0.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 583,002 shares of company stock valued at $9,897,927 over the last quarter. Company insiders own 6.40% of the company’s stock.

Adaptive Biotechnologies Trading Up 0.6%

Shares of Adaptive Biotechnologies stock opened at $16.12 on Tuesday. The company has a fifty day simple moving average of $16.87 and a 200-day simple moving average of $15.77. The stock has a market cap of $2.48 billion, a price-to-earnings ratio of -40.30 and a beta of 2.19. Adaptive Biotechnologies Corporation has a 12-month low of $6.26 and a 12-month high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The firm had revenue of $71.68 million during the quarter, compared to analysts’ expectations of $59.38 million. During the same period in the previous year, the company earned ($0.23) earnings per share. Adaptive Biotechnologies’s quarterly revenue was up 51.0% compared to the same quarter last year. On average, analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

ADPT has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 21st. Wall Street Zen raised shares of Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a report on Sunday, February 8th. TD Cowen reiterated a “buy” rating on shares of Adaptive Biotechnologies in a research note on Friday, February 6th. JPMorgan Chase & Co. increased their price objective on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Friday, February 6th. Finally, Morgan Stanley started coverage on shares of Adaptive Biotechnologies in a report on Monday, December 1st. They issued an “equal weight” rating and a $21.00 price objective on the stock. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $18.25.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.